Literature DB >> 2197012

Activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) to mutagenic metabolites.

M H Buonarati1, J S Felton.   

Abstract

Metabolism of heterocyclic amines to N-hydroxy intermediates appears critical in the mutagenic and carcinogenic actions of these compounds. We have studied the murine hepatic microsomal and cytosolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a heterocyclic amine mutagen formed in cooked meats. PhIP (25 microM) was almost completely converted to N-hydroxy-PhIP and 4'-hydroxy-PhIP in 30 min by reaction with 3-methylcholanthrene-induced microsomal preparations. Microsomal formation of the active N-hydroxy-PhIP metabolite was slightly favored over the 4'-hydroxy-PhIP detoxification product at all concentrations studied (25-200 microM). Metabolism of PhIP in microsomal preparations derived from control mice was approximately 10% of the induced preparations. Metabolically activated PhIP and synthetic N-hydroxy-PhIP produced concentration-dependent increases in mutagenic activity in both Salmonella strains TA98 and TA98/1,8-DNP6, indicating that acetylated intermediates were not important in the mutagenicity of N-hydroxy-PhIP in these bacteria. Significant stabilization of the N-hydroxy-PhIP intermediate by both microsomal protein and BSA was observed. Addition of cytosol to microsomal incubations with PhIP (25 microM) resulted in an increase in mutagenic activity which could be attributable to stabilization by glutathione. An additional increase in mutagenicity resulted from addition of 3'-phosphoadenosine 5'-phosphosulfate (PAPS), but not acetyl coenzyme A to microsomal preparations containing the cytosolic fraction. Furthermore, addition of PAPS to cytosolic preparations containing synthetic N-hydroxy-PhIP produced a 17% decrease in levels of the arylhydroxylamine relative to controls over 30 min, suggesting that secondary metabolism of N-hydroxy-PhIP to a sulfate conjugate may be relevant to the mutagenic and carcinogenic actions of PhIP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197012     DOI: 10.1093/carcin/11.7.1133

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Metabolic enzyme considerations in cancer therapy.

Authors:  Amit K Jain; Sweta Jain; A C Rana
Journal:  Malays J Med Sci       Date:  2007-01

2.  Detection and quantitation of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine adducts in DNA using online column-switching liquid chromatography tandem mass spectrometry.

Authors:  Rajinder Singh; Volker M Arlt; Colin J Henderson; David H Phillips; Peter B Farmer; Gonçalo Gamboa da Costa
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-06-11       Impact factor: 3.205

3.  Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts.

Authors:  J Bendaly; K J Metry; M A Doll; G Jiang; J C States; N B Smith; J R Neale; J L Holloman; W M Pierce; D W Hein
Journal:  Xenobiotica       Date:  2009-05       Impact factor: 1.908

4.  Resistance of bulky DNA lesions to nucleotide excision repair can result from extensive aromatic lesion-base stacking interactions.

Authors:  Dara A Reeves; Hong Mu; Konstantin Kropachev; Yuqin Cai; Shuang Ding; Alexander Kolbanovskiy; Marina Kolbanovskiy; Ying Chen; Jacek Krzeminski; Shantu Amin; Dinshaw J Patel; Suse Broyde; Nicholas E Geacintov
Journal:  Nucleic Acids Res       Date:  2011-07-15       Impact factor: 16.971

5.  Ethanol potentiates the genotoxicity of the food-derived mammary carcinogen PhIP in human estrogen receptor-positive mammary cells: mechanistic support for lifestyle factors (cooked red meat and ethanol) associated with mammary cancer.

Authors:  Durr-E-Shahwar Malik; Rhiannon M David; Nigel J Gooderham
Journal:  Arch Toxicol       Date:  2018-01-23       Impact factor: 5.153

6.  Detection of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo[4,5-b]pyridine in broiled beef.

Authors:  R Kurosaka; K Wakabayashi; H Ushiyama; H Nukaya; N Arakawa; T Sugimura; M Nagao
Journal:  Jpn J Cancer Res       Date:  1992-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.